Treatment of Achondroplasia
modified recombinant human C-type natriuretic peptide (CNP)
Target
NPR2 [HSA:4882] [KO:K12324]
Pathway
hsa04022
cGMP-PKG signaling pathway
hsa04270
Vascular smooth muscle contraction
hsa04921
Oxytocin signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BX Other drugs affecting bone structure and mineralization
M05BX07 Vosoritide
D11190 Vosoritide (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11190 Vosoritide (USAN/INN); Vosoritide (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Lyases (EC4)
Phosphorus-oxygen lyases
NPR2
D11190 Vosoritide (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11190
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11190
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11190
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11190